These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37955340)

  • 21. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
    Lau HCH; Sung JJ; Yu J
    Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
    Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
    Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the sex hormone-gut microbiome axis in tumor immunotherapy.
    Wang L; Tang L; Zhai D; Song M; Li W; Xu S; Jiang S; Meng H; Liang J; Wang Y; Zhang B
    Gut Microbes; 2023; 15(1):2185035. PubMed ID: 36880651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unraveling the gut microbiome's contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives.
    Tabrizi E; Pourteymour Fard Tabrizi F; Mahmoud Khaled G; Sestito MP; Jamie S; Boone BA
    Front Immunol; 2024; 15():1434771. PubMed ID: 39044834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
    Najafi S; Majidpoor J; Mortezaee K
    Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
    Duttagupta S; Hakozaki T; Routy B; Messaoudene M
    Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.
    Xu H; Cao C; Ren Y; Weng S; Liu L; Guo C; Wang L; Han X; Ren J; Liu Z
    Front Immunol; 2022; 13():949490. PubMed ID: 36177041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
    Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
    Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex interactions between the microbiome and cancer immune therapy.
    Schwartz DJ; Rebeck ON; Dantas G
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.
    Xia L; Zhu X; Wang Y; Lu S
    Cancer Lett; 2024 Aug; 598():217123. PubMed ID: 39033797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy.
    Singh A; Alexander SG; Martin S
    Front Immunol; 2023; 14():1114499. PubMed ID: 37261348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
    Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
    Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
    Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era.
    Spyrou N; Vallianou N; Kadillari J; Dalamaga M
    Semin Cancer Biol; 2021 Aug; 73():356-376. PubMed ID: 33989733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
    Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
    Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.
    Hazra R; Chattopadhyay S; Mallick A; Gayen S; Roy S
    Med Oncol; 2024 Jun; 41(7):175. PubMed ID: 38874788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
    Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
    Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.
    Simpson RC; Shanahan ER; Scolyer RA; Long GV
    Nat Rev Clin Oncol; 2023 Oct; 20(10):697-715. PubMed ID: 37488231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.